Item 2.02. Results of Operations and Financial Condition.
Although it has not finalized its full financial results for the fourth quarter
and fiscal year ended December 31, 2020, Verona Pharma plc (the "Company")
expects to report that it had approximately $188.0 million in cash and cash
equivalents as of December 31, 2020.
The information contained in this Item 2.02 of this Current Report on Form 8-K
(the "Form 8-K") is unaudited and preliminary, and does not present all
information necessary for an understanding of the Company's financial condition
as of December 31, 2020 and its results of operations for the three months and
year ended December 31, 2020. The audit of the Company's financial statements
for the year ended December 31, 2020 is ongoing and could result in changes to
the information set forth above.
The information contained in this Item 2.02 of the Form 8-K shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
Section, nor shall it be deemed to be incorporated by reference into any filing
of the Company under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
This Form 8-K contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this Form 8-K that do not relate to matters of historical fact should be
considered forward-looking statements, including statements regarding the
Company's expected financial results for the fourth quarter and fiscal year
ended December 31, 2020. These forward-looking statements are based on
management's current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or achievements
to be materially different from our expectations expressed or implied by the
forward-looking statements, including without limitation general business,
financial and accounting risks, and the other important factors discussed under
the caption "Risk Factors" in our Registration Statement on Form F-1 filed with
the SEC on August 17, 2020 and our Report on Form 6-K filed with the SEC on
November 24, 2020, as any such factors may be updated from time to time in our
other filings with the SEC, which are accessible on the SEC's website at
www.sec.gov and the Investors page of our website at
www.veronapharma.com/investors. Any such forward-looking statements represent
management's estimates as of the date of this Form 8-K. While we may elect to
update such forward-looking statements at some point in the future, we disclaim
any obligation to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as representing our
views as of any date subsequent to the date of this Form 8-K.
© Edgar Online, source Glimpses
VERONA PHARMA PLC 
